US2014286891A1PendingUtilityA1
Ion binding polymers and uses thereof
Est. expiryMar 30, 2024(expired)· nominal 20-yr term from priority
A61P 9/00A61P 39/04A61P 7/00A61P 9/12A61P 39/02A61P 7/08A61P 9/04A61P 7/10A61P 3/12A61P 3/00A61P 3/04A61P 13/12A61P 1/16A61K 31/74A61K 31/795C08F 128/02A61K 31/78A61K 45/06A61K 31/785A61K 9/5031C08F 120/06A61K 9/1635A61K 31/80A61K 9/14A61K 9/5026A61K 9/28
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Claims
exact text as granted — not AI-modified1 .- 33 . (canceled)
34 . A method for treating hyperkalemia in a patient in need thereof comprising:
administering to the patient a composition comprising a pharmaceutically acceptable excipient and a crosslinked polymer comprising at least one monomeric unit having at least one cation exchange moiety selected from
in the form of a bead.
35 . The method of claim 34 , wherein the patient suffers from hyperkalemia resulting from renal insufficiency caused by treatment with a potassium-sparing diuretic, an angiotensin-converting enzyme inhibitor, an angiotensin receptor blocker, a non-steroidal anti-inflammatory drug, heparin, or trimethoprim.
36 . The method of claim 34 , wherein the patient is co-administered a potassium-sparing diuretic, an angiotensin-converting enzyme inhibitor, an angiotensin receptor blocker, a non-steroidal anti-inflammatory drug, heparin, or trimethoprim.
37 . The method of claim 34 , wherein the bead form results from a heterogeneous polymerization process.
38 . The method of claim 37 wherein the heterogeneous polymerization process is suspension polymerization.
39 . The method of claim 36 wherein the bead form results from a heterogeneous polymerization process.
40 . The method of claim 39 wherein the heterogeneous polymerization process is suspension polymerization.
41 . The method of claim 34 wherein the crosslinked polymer comprises an alpha-fluoroacrylate polymer.
42 . The method of claim 34 wherein the polymer comprises methyl 2-fluoroacrylate monomeric units.
43 . The method of claim 37 wherein the polymer is produced from a polymerization mixture comprising a free radical initiator.
44 . The method of claim 43 wherein the polymer is produced from a polymerization mixture further comprising a water-soluble salt.
45 . The method of claim 34 wherein the crosslinked polymer comprises a cationic counterion of Ca 2+ .
46 . The method of claim 36 wherein the crosslinked polymer comprises a cationic counterion of Ca 2+ .
47 . The method of claim 34 wherein the acid group of the cation exchange moiety is in its protonated, ionized or anhydride form.
48 . The method of claim 36 wherein the acid group of the cation exchange moiety is in its protonated, ionized or anhydride form.
49 . The method of claim 34 wherein the polymer is an alpha-fluoroacrylic acid polymer crosslinked with divinylbenzene, ethylene bisacrylamide, N,N′-bis(vinylsulfonylacetyl)ethylene diamine, 1,3-bis(vinylsulfonyl) 2-propanol, vinylsulfone, N,N′-methylenebisacrylamide polyvinyl ether, polyallylether, or a combination thereof.
50 . The method of claim 49 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinylbenzene.
51 . The method of claim 36 wherein the polymer is an alpha-fluoroacrylic acid polymer crosslinked with divinylbenzene, ethylene bisacrylamide, N,N′-bis(vinylsulfonylacetyl)ethylene diamine, 1,3-bis(vinylsulfonyl)2-propanol, vinylsulfone, N,N′-methylenebisacrylamide polyvinyl ether, polyallylether, or a combination thereof.
52 . The method of claim 51 wherein the alpha-fluoroacrylic acid polymer is crosslinked with divinylbenzene.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.